A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues.
Kathleen M Sicinski, Damla Sürmeli, Jasper Du, Venkata S Raman, Vittorio Montanari, Minhee Lee, Benjamin N Harwood, Alan S Kopin, Martin Beinborn, Krishna Kumar
Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Kathleen M SicinskiDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
Damla SürmeliDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.ORCID 0009-0000-7937-1522
Jasper DuDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
Venkata S RamanDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
Vittorio MontanariDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
Minhee LeeDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
Benjamin N HarwoodMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts 02111, United States.
Alan S KopinMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts 02111, United States.
Martin BeinbornDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
Krishna KumarDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.ORCID 0000-0002-0548-5014
Tufts University · USTufts Medical Center · US
Funding
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic SyndromeR42DK131842 · NIDDK · VELUM, INC. · PI BEINBORN, MARTIN, KUMAR, KRISHNA · 2024 to 2025
$2.1M
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1R42AG061909 · NIA · VELUM, INC. · PI BEINBORN, MARTIN, KUMAR, KRISHNA · 2021 to 2023
$1.7M
Protease Stable N-Terminally Modified Therapeutic PeptidesR41DK131842 · NIDDK · VELUM, INC. · PI KUMAR, KRISHNA · 2022 to 2022
$367k
Triagonist Peptide Therapeutics for NeuroprotectionR41GM142448 · NIGMS · VELUM, INC. · PI KUMAR, KRISHNA · 2021 to 2021
$260k
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1R41AG061909 · NIA · VELUM, INC. · PI BEINBORN, MARTIN · 2018 to 2018
$225k
Design of Protease Stable Therapeutic Peptides by Non-Perturbative ModificationR41GM130257 · NIGMS · VELUM, INC. · PI KUMAR, KRISHNA · 2018 to 2018
Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid peptide hormone that regulates postprandial glucose levels. GIP binds to its cognate receptor, GIPR, and mediates metabolic physiology by improved insulin sensitivity, β-cell proliferation, increased energy consumption, and stimulated glucagon secretion. Dipeptidyl peptidase-4 (DPP4) catalyzes the rapid inactivation of GIP within 6 min
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues. · full record | OpenQuestion